Cell Culture Media Market Size to Hit USD 10.5 Billion by 2030

According to Vision Research Report, the global cell culture media market size is expected to hit around USD 10.5 billion by 2030, growing at a CAGR of 12.57% from 2022 to 2030

Report Highlights

  • The SFM segment held the highest revenue share of 35.96% in 2021. 
  • The biopharmaceutical production segment dominated the market with a share of 43.38% in 2021. 
  • The liquid media segment captured the highest revenue share of 62.65 in 2021. 
  • The pharma and biopharma companies segment captured the highest revenue share of 34.6% in 2021. 
  • North America dominated the market and accounted for the largest revenue share of 38.27% in 2021. 

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39426

Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies.  The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

Scope of The Report

Report Coverage


Market Size in 2021

USD 3,616.94 million

Revenue Forecast by 2030

USD 10.5 billion

Growth rate from 2022 to 2030

CAGR of 12.57%

Base Year


Forecast Period

2022 to 2030


Product, application, type, end-user, region

Companies Covered

Thermo Fisher Scientific Inc.; Merck KGaA; CYTIVA; Sartorius AG; FUJIFILM Irvine Scientific, Inc.; Lonza Group AG; InvivoGen; STEMCELL Technologies Inc.; PromoCell GmbH; Cell Biologics, Inc.


The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

Product Insights

The SFM segment held the highest revenue share of 35.96% in 2021. The use of SFM signifies a significant tool, which allows the researchers to perform specific application or grow a specific cell type without using serum. Advantages of using SFM include increased growth and/or productivity, more consistent performance, better control over physiological sensitivity, and to diminish the risk of infection by serum-borne adventitious agents in the culture. In addition, serum-free alternatives better serve the animal welfare which is the major factor driving the adoption of SFM.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39426

In addition, the field of gene and cell therapy is rapidly growing, and the Food and Drug Administration regulatory guidelines are demanding more control of raw materials to sustain the reliable and safe manufacturing of drug products. The use of SFM offers an opportunity to produce additional reproducible formulations and fewer batch-to-batch variability. 

Application Insights

The biopharmaceutical production segment dominated the market with a share of 43.38% in 2021. The biopharmaceutical industry‚Äôs demand for more reproducible and better-defined media to meet the expanding production levels while reducing the risk of contamination in the downstream processes is significantly increasing the demand for this market.

Moreover, strategic activities by key biopharmaceutical companies also drive the segment growth. For instance, in July 2021 Cytiva and Pall Corporation invested USD 1.5 billion for over two years to meet the rising demand for biotechnology solutions. The two companies plan to invest USD 400+ million for culture media in powder or liquid along with expanding its operations in the U.S., Austria, and U.K.

Type Insights

The liquid media segment captured the highest revenue share of 62.65 in 2021. An increasing number of biologics and biosimilars manufacturers, both downstream and upstream, are switching from premixed powders to liquid media owing to the factors such as rapid mycobacterial growth and high rate of isolation. Moreover, it eradicates a few process steps, and also reduces the probability of hazardous exposure, and makes manufacturing and development more flexible and simpler than powdered media. In addition, ready-to-use liquid media also eliminates the need for mixing containers, balances, and installation of water for injection (WFI) loop which is needed for mixing powder media.

The segment is also being driven by the strategic activities of the manufacturers, for instance, in June 2021, Sartorius, opened its new site in Israel, which focuses on customized and specialty cell culture mainly for the advanced therapies market. This site will serve as a significant production site for buffers and liquid cell culture.

End-user Insights

The pharma and biopharma companies segment captured the highest revenue share of 34.6% in 2021. The expansion of the current manufacturing capacities for biopharmaceuticals drives the demand for cell culture products. For instance, in September 2020, Cytiva, announced the expansion of its manufacturing capacity and hiring personnel in significant areas to support the growth of the biotechnology industry. The company has planned investment of around USD 500 million for five years to increase the manufacturing capacity.

In addition, increasing clinical trials will further offer lucrative opportunities in the review period. For instance, in 2021, the number of industry-sponsored trials in progress for regenerative medicine augmented by 100 as compared to 2020, bringing the total to 1,320. There were 1,328 regenerative medicine trials in progress worldwide supported by non-industry groups such as government entities and academic centers.        

Regional Insights

North America dominated the market and accounted for the largest revenue share of 38.27% in 2021. This major share can be attributed to the growth in the pharmaceutical and biotechnology industries, mounting approvals for cell culture-based vaccines, and rising incidence of diseases such as cancer coupled with investments and funding in cell-based research.

In Asia Pacific, the market is estimated to grow fast owing to the increase in awareness associated with the use of the cell culture technique. Furthermore, strategic activities by key players to expand their presence in the Asia Pacific countries to capture high market share is expected to offer lucrative opportunities. For instance, In December 2021, Fujifilm Irvine Scientific, Inc., in China started the construction to build its new bioprocessing center, with the aim to ensure cell culture media optimization support for biotherapeutic drug development, vaccines, and advanced therapies.

Key Players

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Sartorius AG
  • FUJIFILM Irvine Scientific, Inc.
  • Lonza Group AG
  • InvivoGen 
  • STEMCELL Technologies Inc.
  • PromoCell GmbH
  • Cell Biologics, Inc.

Market Segmentation

  • By Product Outlook
    • Serum-free Media
      • CHO Media
      • BHK Medium    
      • Vero Medium   
      • HEK 293 Media   
      • Other Serum-free media
    • Classical Media
    • Stem Cell Culture Media
    • Specialty Media
    • Chemically Defined Media
    • Other Cell Culture Media
  • By Application Outlook
    • Biopharmaceutical Production
      •  Monoclonal Antibodies
      •  Vaccines Production
      •  Other Therapeutic Proteins
    • Diagnostics
    • Drug Screening And Development
    • Tissue Engineering And Regenerative Medicine
      • Cell And Gene Therapy
      • Other Tissue Engineering And Regenerative Medicine Applications
    • Other Applications
  • By Type Outlook
    • Liquid Media
    • Semi-solid And Solid Media
  • By End-user Outlook
    • Pharmaceutical And Biotechnology Companies
    • Hospitals And Diagnostic Laboratories
    • Research And Academic Institutes
    • Other End-users
  • By Regional Outlook
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39426

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333


Back to news